ERBB2 and breast carcinoma: Numerous clients of Hsp90, including survivin (Brady et al., 2015) and proteins of alternative HER2 survival pathways (Ye et al., 2021), also contribute to reversing lapatinib resistance in HER2-positive breast cancer cells.